

## Draft Guidance on Daclatasvir Dihydrochloride

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

**Active Ingredient:** Daclatasvir dihydrochloride

**Dosage Form; Route:** Tablet; oral

**Recommended Studies:** Two studies

1. Type of study: Fasting  
Design: Single-dose, two-way crossover in vivo  
Strength: EQ 60 mg Base  
Subjects: Healthy males and females (nonpregnant), general population  
Additional comments: The bioequivalence (BE) study should be conducted without co-administration of sofosbuvir

---

2. Type of study: Fed  
Design: Single-dose, two-way crossover in-vivo  
Strength: EQ 60 mg Base  
Subjects: Healthy males and females (nonpregnant), general population  
Additional comments: See comment above

---

**Analytes to measure (in appropriate biological fluid):** Daclatasvir in plasma

**Bioequivalence based on (90% CI):** Daclatasvir

**Waiver request of in vivo testing:** EQ 30 mg base strength based on (i) acceptable bioequivalence studies on the strength EQ 60 mg base, (ii) acceptable in-vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods Web site, available to the public at the following location: <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).